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Abstract
Background: When aromatase inhibitors are used to treat premenopausal women with endometriosis, additional
drugs should be used to effectively down-regulate gonadal estrogen biosynthesis. This randomized prospective
open-label study compared the efficacy in treating pain symptoms and the tolerability of letrozole combined with
either norethisterone acetate or triptorelin.
Methods: Women with pain symptoms caused by rectovaginal endometriosis were treated with letrozole
(2.5 mg/day) and were randomized to also receive either oral norethisterone acetate (2.5 mg/day; group N) or
intramuscular injection of triptorelin (11.25 mg every 3 months; group T). The scheduled length of treatment was 6
months. A visual analogue scale and a multidimensional categorical rating scale were used to assess the severity of
pain symptoms. The volume of the endometriotic nodules was estimated by ultrasonography using virtual organ
computer-aided analysis. Adverse effects of treatment were recorded.
Results: A total of 35 women were randomized between the two treatment protocols. Significantly more
patients in group N rated their treatment as satisfactory or very satisfactory (64.7%) as compared to group T
(22.2%; p = 0.028). The intensity of both non-menstrual pelvic pain and deep dyspareunia significantly
decreased during treatment in both study groups, though no statistically meaningful difference between the
two groups was apparent. Reduction in the volume of endometriotic nodules was significantly greater in
group T than in group N. Interruption of treatment due to adverse effects significantly differed between the
groups, with 8 women in group T (44.4%) and 1 woman in group N (5.9%) interrupting treatment (p = 0.018).
Similarly, 14 women included in group T (77.8%) and 6 women included in group N (35.3%) experienced
adverse effects of treatment (p = 0.018). During treatment, mineral bone density significantly decreased in
group T but not in group N.
Conclusions: Aromatase inhibitors reduce the intensity of endometriosis-related pain symptoms. Combining
letrozole with oral norethisterone acetate was associated with a lower incidence of adverse effects and a lower
discontinuation rate than combining letrozole with triptorelin.
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Over the last 10 years, several studies showed that the
administration of aromatase inhibitors significantly
reduces the severity of pain symptoms caused by
endometriosis [1]. In premenopausal women, aromatase
inhibitors decrease the concentration of circulating
estrogens and cause an increase in FSH secretion
leading to a stimulatory effect on the growth of ovarian
follicles [2]. In line with this, it has been shown that the
daily oral administration of letrozole and desogestrel in
women with rectovaginal endometriosis results in the
development of functional ovarian cysts [3]. Similarly,
functional ovarian cysts developed in over 50% of
patients with symptomatic uterine leiomyomas treated
with letrozole monotherapy for three months [4] and in
24% of women receiving letrozole for two months after
laparoscopic treatment of endometriosis [5]. Therefore,
when aromatase inhibitors are administered to preme-
nopausal women, additional drugs should be used to
effectively down-regulate the ovaries and gonadal estro-
gen biosynthesis [6].
Previous studies in women with endometriosis com-
bined aromatase inhibitors (letrozole or anastrozole)
with combined oral contraceptive pills [7], norethister-
one acetate [8-12] or gonadotropin-releasing hormone
analogues [13,14]. However, there are currently no pub-
lished studies comparing pain symptoms and adverse
effects when gonadotropin-releasing hormone analogue
and progestin are administered in combination with aro-
matase inhibitors.
Given this background, the current study investigated
whether the administration of progestin or gonadotro-
pin-releasing hormone analogue in combination with
letrozole has different efficacy and tolerability in women
with rectovaginal endometriosis.
Methods
This prospective, randomized, open-label trial compared
the efficacy of letrozole combined with either norethis-
terone acetate or triptorelin in the treatment of pain
symptoms caused by rectovaginal endometriosis. The
study was performed in an academic centre for the
diagnosis and treatment of endometriosis. The primary
end point of the study was to compare the changes in
pain symptoms during the 6-month treatment with the
two study protocols. The secondary objective of the
study was to evaluate the incidence of adverse effects.
The tertiary objective of the study was to evaluate the
changes in the volume of the rectovaginal nodules
during treatment.
The local Institutional Review Board approved the
study protocol. The patients enrolled in the study signed
a written informed consent.
Study population
Women who participated had previously undergone
laparoscopy or laparotomy for symptomatic endometrio-
sis in other hospitals but deep endometriotic lesions
were not excised; however, the presence of endometrio-
sis was histologically diagnosed. These patients had
recurrent or persistent pain symptoms after surgery.
Patients included in the study had pain symptoms of
more than 12-months duration and wished to avoid
further surgery. Only premenopausal women were
included in the study.
The diagnosis of rectovaginal endometriosis was based
on vaginal and rectal examinations and confirmed by
rectal water contrast transvaginal ultrasonography
[15-17]. Patients with gastrointestinal complains sugges-
tive of bowel endometriosis underwent multidetector
computerized tomography enteroclysis [18-20]. Kidney
and urinary tract evaluations were always performed.
The exclusion criteria for the study were: uropathy or
endometriotic nodules determining bowel stenosis; ovar-
ian endometrioma of diameter > 3 cm; therapies for
endometriosis other than nonsteroidal anti-inflammatory
drugs in the three months before inclusion in the study
(six months for GnRH analogues); previous use of
aromatase inhibitors; unwillingness to tolerate menstrual
changes; undiagnosed vaginal bleeding; osteopenia or
osteoporosis; current or past history of seizure disorders;
pulmonary, cardiac, hepatic, or renal diseases; throm-
boembolic or cerebrovascular events; pregnancy; psy-
chiatric disturbances; and history of drug or alcohol
abuse.
Study protocol and randomization
All study patients received letrozole (2.5 mg/day,
Femara; Novartis Farma, Varese, Italy), elemental cal-
cium (1000 mg/day), and vitamin D3 (880 IU/day,
Cacit-Vitamina D3; Procter & Gamble, Rome, Italy;
group L). In addition, they were randomized to receive
either oral norethisterone acetate (2.5 mg/day, Primolut-
Nor; Schering, Milan, Italy; group N) or depot intramus-
cular injection of the 3-month formulation of triptorelin
(11.25 mg; Decapeptyl, Ipsen Pharma, Milan, Italy;
group T). The scheduled length of treatment was
6 months.
Randomization was performed 1:1 by using a compu-
ter-generated randomization list prepared by an inde-
pendent statistician not involved in the rest of the
investigation. Based on the list, sequentially numbered
sealed opaque envelope containing cards with group
assignment were prepared. These sealed envelopes
marked with the patients’ sequential numbers were kept
at the endometriosis clinic. When a patient was enrolled
and written informed consent obtained, the envelope
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treatment was assigned.
Subjects were allowed to take nonsteroidal anti-
inflammatory drugs when needed (naproxen sodium,
550 mg tablet, Synflex Forte 550, Recordati Industria
Chimica e Farmaceutica, Milan, Italy); however, they
were asked to record the number of tablets used each
month during treatment.
Complete blood count, serum electrolytes, kidney and
liver function tests, along with lipids were performed
before the onset of therapy, every two months during
treatment, and at the completion of treatment. A bone
densitometry determination of the hip and lumbar spine
(by dual-energy X-ray absorptiometry or DEXA scan)
was performed within one month before the onset of
the study and was repeated within one month after
completion of the treatment.
Evaluation of symptoms
Each patient was asked to complete a questionnaire on
the presence and severity of dysmenorrhea, nonmenstr-
ual pelvic pain, and deep dyspareunia. The severity of
pain symptoms was measured using a 10-cm visual
analogue scale (VAS) as previously described [10]. A
score of 0.1 to 5.0 was considered mild pain, 5.1 to 8.0
moderate pain, and 8.1 to 10.0 severe pain. Patients
enrolled in the study had at least one moderate or
severe symptom. In addition, patients were asked to
complete a questionnaire investigating the presence and
severity of dysmenorrhea, deep dyspareunia, and
nonmenstrual pelvic pain graded with a 0-to 3-point
multidimensional categorical rating scale modified from
the one devised by Biberoglu and Behrman [21] and
previously described by other authors [22]. This scale
defines dysmenorrhea according to loss of work effi-
ciency and need for bed rest (absence of pain, 0; some
loss of work efficiency, mild, 1; in bed part of 1 day,
occasional loss of work, moderate, 2; in bed for 1 or
more days, incapacitation, severe, 3); nonmenstrual pel-
vic pain according to various degrees of discomfort and
use of analgesics (absence of pain, 0; occasional pelvic
d i s c o m f o r t ,m i l d ,1 ;n o t i c e a b le discomfort for most of
the cycle, moderate, 2; pain persisting during the cycle
or requiring strong analgesics, severe, 3); and deep
dyspareunia according to limitation of sexual activity
(no discomfort, 0; tolerated discomfort, mild, 1; inter-
course painful to the point of interruption, moderate, 2;
intercourse avoided because of pain, severe, 3).
Severity of symptoms was evaluated before starting the
treatment and after 3 and 6 months of treatment.
After the completion of treatment or at the time of
interruption of treatment, the women rated the overall
degree of satisfaction with their treatment by answering
to the following question: “Taking into consideration
the variations in pain symptoms, in overall well-being
and quality of life, as well as the adverse effects experi-
enced, if any, how would you define the level of satisfac-
tion with your treatment?” as described previously
[23,10]. Answers were based on a 5-point Likert scale
(very satisfied, satisfied, uncertain, dissatisfied, very
dissatisfied). Adverse effects experienced during the
6-month treatment were recorded during monthly
consultations.
Evaluation of the volume of rectovaginal nodules
The volume of the endometriotic nodules was estimated
by ultrasonography before commencement and after
completion of 6 months hormonal therapy. Ultrasound
examinations were performed using a Voluson i ultra-
sound machine (GE Healthcare, Milwaukee, WI, USA)
connected to a transvaginal transducer. The volume of
the rectovaginal endometriotic nodules was estimated by
virtual organ computer-aided analysis (VOCAL™,G E
Healthcare, Milwaukee, WI, USA) [24]. The VOCAL™
technique was used to obtain a sequence of 20 sections
of each endometriotic nodule around a fixed axis, from
the proximal to the distal part of the nodule, each after
9° rotation from the previous section, which represents
the best compromise between reliability, validity and
time to define the volume [25]. The contour of each
nodule was drawn manually by using the roller ball
cursor of the 3D ultrasound machine to obtain a 3D
volume measurement. Each measurement was
p e r f o r m e do f f - l i n ea f t e rs c a n n i n gb yas i n g l et r a i n e d
operator who was not aware of the type of hormonal
therapy administered to the patients. The time required
to perform these measurements ranged from 10 to
15 minutes.
Power analysis
In calculating the sample size required for this rando-
mized study, it was considered that a previous study
including women with rectovaginal endometriosis
reported that 56% of the patients were satisfied after
6-month treatment with norethisterone acetate and
letrozole [10]. A difference of 30% in the satisfaction
rate between the two study groups was considered clini-
cally relevant. To have an 80% chance of detecting such
a difference at an overall statistical significance level of
5%, 35 patients per group were required. Allowing for
dropouts, the aim was to recruit a total of about
80 women. The study was ended pre-term based on the
results of an interim analysis.
Statistical analysis
The baseline characteristics of the study population
were compared by using the student t test, c
2 test or
Fisher’s exact test as appropriate. The student t test was
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sured on the VAS scale between the two study groups.
The Mann-Whitney rank sum test was used to compare
the intensity of pain symptoms measured on the multi-
dimensional categorical rating scale between the two
study groups. The paired t-test and the Wilcoxon signed
rank test were used to compare the intensity of pain
symptoms before and after treatment. P < 0.05 was con-
sidered statistically significant. Data were analyzed using
the Sigma Stat software version 3.5 and the SPSS soft-
ware version 13.0 (SPSS Science, Chicago, IL, USA).
Results
The diagrammatic flow of the participants is given in
Figure 1. Out of 40 women approached for the study,
35 patients (87.5%) gave their consent and were rando-
mized to receive one of the treatments. At the time of
the interim analysis, 18 were allocated to group T and
17 women were allocated to group N.
The mean ( ± SD) age was similar in group T (35.0 ±
3.6 years) and in group N (35.2 ± 4.0; p = 0.857).
E i g h tw o m e ni ng r o u pT( 4 4 . 4 % )a n d1w o m a ni n
group N interrupted the treatment because of adverse
effects (5.9%) (p = 0.018). In group T, the 8 patients
interrupted the treatment after a mean ( ± SD) time of
3.9 ( ± 1.0) months; the woman in group N interrupted
the treatment after 4 months.
After the completion of treatment or at the time of
interruption of treatment, in group T, 2 women (11.1%)
were very dissatisfied, 10 women (55.6) were dissatisfied,
2 women (11.1%) were uncertain, 3 (16.7%) women
were satisfied and 1 woman (5.6%) was very satisfied.
In group N, 1 woman (5.9%) was very dissatisfied,
4 women (23.5%) were dissatisfied, 1 (5.9%) woman was
uncertain, 8 women (47.1%) were satisfied and 3 (17.6%)
women were very satisfied. Therefore, 4 women (22.2%)
w e r es a t i s f i e do rv e r ys a t i s f i e di ng r o u pTa n d1 1
women (64.7%) were satisfied or very satisfied in group
N (p = 0.028).
Table 1 shows the intensity of pain symptoms at base-
line and during treatment. The baseline intensity of the
symptoms was similar in the two study groups both on
the VAS scale and on the multidimensional categorical
rating scale.
The intensity of both nonmenstrual pelvic pain and
deep dyspareunia were significantly lower at 3-and
6-month when compared with baseline values in both
study groups. The intensity of pain symptoms was simi-
lar in group T and in group N at both 3-and 6-month
treatment in both scales.
When the intensity of pain symptoms at 6-month was
compared with the intensity of pain symptoms at
3-month, a significant decrease of nonmenstrual pelvic
pain measured on the VAS scale was observed in group T
and group N. The intensity of deep dyspareunia decreased
significantly in group N; there was a trend for a lower
intensity of deep dyspareunia at 6-month compared with
3-month in group T, but the difference did not reach sta-
tistical significance, possibly due to the limited number of
patients who completed the 6-month treatment in this
group. In both study groups, there was no significant dif-
ference in the multidimensional categorical rating scale
scores between 3-and 6-month assessments.
At baseline, the volume of the rectovaginal endome-
triotic nodules was similar in group T (mean ± SD, 3.2
±0 . 9c m
3) and in group N (3.4 ± 1.0 cm
3; p = 0.689).
After 6 months of treatment, there was a significant
reduction in the volume of the endometriotic nodules in
both study groups (group T, p = 0.001; group N, p <
0.001). The mean ( ± SD) percentage reduction in the
volume of the endometriotic nodules was significantly
higher in group T (16.1 ± 10.0%) than in group N (10.2
± 6.3%; p = 0.048).
The mean ( ± SD) number of naproxen sodium tablets
used per patient each month was 6.7 ( ± 4.5) in group T
and 6.5 ( ± 5.0) in group N (p = 0.904). When com-
pared with baseline values, the mean ( ± SD) number of
naproxen sodium tablets used per patient each month
after 3 months of treatment significantly decreased both
in group T (2.6 ± 2.2; p < 0.001) and in group N (2.6 ±
2.8; p < 0.001). After 6 months of treatment, the num-
ber of monthly naproxen sodium tablets used per
patient was further decreased in group N (1.4 ± 1.3)
when compared with 3-month treatment (p = 0.042).
After 6-month treatment, in group T, there was a trend
for the number of naproxen sodium tablets used per
patient each month to be lower (1.8 ± 1.2) than at
3-month treatment but the difference did not reach
statistical significance (p = 0.070).
14 women included in group T (77.8%) and 6 women
included in group N (35.3%) experienced adverse effects
Figure 1 Flow chart showing recruitment and women’s
progress through the study.
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effects of treatment experienced by patients included in
the two study groups; arthralgia was significantly more
frequent in group T than in group N. In group T, the
main reasons for interruption of treatment were arthral-
gia in 5 women, hot flushes and hair loss in 2 women,
decreased libido in 2 women, arthralgia and hot flushes
in 1 woman, arthralgia and myalgia in 1 woman, hot
flushes and depression in 1 woman, myalgia in 1 woman
and depression in 1 woman. In group N, the main rea-
sons for interruption of treatment were weight gain in 2
women, arthralgia in 1 woman, breakthrough bleeding
in 1 woman, depression in 1 woman and decreased
libido in 1 woman.
There were no adverse effects on blood count, liver
function, renal function, and lipid profile (data not
shown).
At the completion of the 6-month treatment, DEXA
scans showed that patients included in group T had a
significant decrease in the mineral bone density both in
the lumbar spine (p = 0.019) and in the hip (p = 0.002).
In group N, DEXA scans showed no significant change
in the mineral bone density both in the lumbar spine
(p = 0.192) and in the hip (p = 0.221). No woman fell
into the category of osteopenia at the conclusion of the
treatment.
Discussion
Hormonal therapies are not curative of endometriosis,
therefore, they should be chronically administered to
women with endometriosis [26]. Viewed from this per-
spective, the incidence of adverse effects is particularly
Table 1 Intensity of pain symptoms at baseline and during treatment
VAS scale Multidimensional categorical rating scale
group T
(n = 18)
group N
(n = 17)
p group T
(n = 18)
group N
(n = 17)
p
Dysmenorrhea
- baseline 8.7 ± 1.1
(n = 18)
8.6 ± 1.3
(n = 16)
0.881 3 (2-3)
(n = 18)
3 (0-3)
(n = 17)
0.890
Nonmenstrual pelvic pain
- baseline 6.1 ± 1.4
(n = 16)
6.0 ± 1.4
(n = 14)
0.783 2 (0-3)
(n = 18)
2 (0-3)
(n = 17)
0.957
- 3 months of treatment 3.2 ± 1.3
(n = 15)
3.3 ± 1.5
(n = 14)
0.782 1 (0-2)
(n = 17)
1 (0-2)
(n = 17)
0.818
- 6 months of treatment 1.2 ± 1.3
(n = 9)
2.0 ± 1.8
(n = 14)
0.286 0 (0-2)
(n = 10)
1 (0-2)
(n = 16)
0.171
p value: 3 month of treatment vs baseline < 0.001 < 0.001 < 0.001 < 0.001
p value: 6 month of treatment vs baseline < 0.001 < 0.001 0.004 < 0.001
p value: 6 month of treatment vs 3 month 0.001 < 0.001 0.063 0.156
Deep dyspareunia
a
- baseline 6.4 ± 1.9
(n = 12)
6.6 ± 2.1
(n = 14)
0.801 2 (0-3)
(n = 14)
2 (0-3)
(n = 15)
0.501
- 3 months of treatment 3.4 ± 1.2
(n = 11)
3.6 ± 1.5
(n = 14)
0.635 1 (0-2)
(n = 13)
1 (0-2)
(n = 15)
0.853
- 6 months of treatment 2.0 ± 0.9
(n = 4)
2.2 ± 1.4
(n = 13)
0.727 1 (0-1)
(n = 6)
1 (0-2)
(n = 14)
0.406
p value: 3 month of treatment vs baseline < 0.001 < 0.001 0.031 < 0.001
p value: 6 month of treatment vs baseline 0.022 < 0.001 0.042 < 0.001
p value: 6 month of treatment vs 3 month of treatment 0.088 < 0.001 0.076 0.125
a14 women included in group T and 15 women included in group N were sexually active at the time of the study
The intensity of each pain symptom was measured only for patients suffering the symptom; the multidimensional categorical rating scale was calculated for all
the patients because this scale includes the 0 for patients not suffering the symptom
Table 2 Adverse effects of treatment experienced by
patients included in the study
Adverse effect group T
(n = 18)
group N
(n = 17)
p
Arthralgia 7 (38.9%) 1 (5.9%) 0.041
Myalgia 3 (16.7%) 1 (5.9%) 0.603
Persistent breakthrough bleeding 0 (0.0%) 2 (11.8%) 0.229
Depression 4 (22.2%) 1 (5.9%) 0.338
Insomnia 3 (16.7%) 0 (0.0%) 0.229
Decreased libido 4 (22.2%) 2 (11.8%) 0.658
Vaginal dryness 3 (16.7%) 0 (0.0%) 0.229
Hot flushes 4 (22.2%) 0 (0.0%) 0.104
Hair loss 2 (11.1%) 0 (0.0%) 0.486
Headache 2 (11.1%) 0 (0.0%) 0.486
Weight gain 1 (5.6%) 2 (11.8%) 0.603
At least one adverse effect 14 (77.8%) 6 (35.3%) 0.018
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This randomized prospective study compared two dif-
ferent therapeutic regimens, demonstrating that co-
treatment with progestin is more accepted by the
patients that co-treatment with gonadotropin-releasing
hormone analogue. In fact, the incidence of adverse
effect is significantly higher when letrozole is combined
with triptorelin than when it is combined with norethis-
terone acetate. In fact, 77.8% of women included in
group T and 35.3% of those included in group N had at
least one adverse effect. In line with this, the percentage
of patients who interrupted the treatment was signifi-
cantly higher in group T than in group N (44.4% versus
5.9%). Because of these reasons, the study was termi-
nated before it reached the full enrolment of 80
subjects.
The risk of adverse effects during treatment with aro-
matase inhibitors is related to the length of treatment. A
short-term administration of aromatase inhibitors (two
or three months) may not cause significant adverse
effects; in the current study only two women (5.7%)
interrupted the treatment before the fourth month of
therapy because of adverse effects. This observation is
consistent with a recent study which reported no signifi-
cant adverse effect of administering letrozole for two
months after laparoscopic treatment of endometriosis
[25]. However, several previous studies showed that a
longer administration of aromatase inhibitors (six
months) might be associated with several adverse effects
[3,7-12]. In contrast with these observations, a prospec-
tive randomized trial comparing the postsurgical admin-
istration of goserelin plus anastrozole to goserelin alone
for 6 months did not describe the occurrence of typical
aromatase inhibitor related adverse effects (such as
arthralgia and myalgia) [13]. It is possible, that the
patients included in our study were more active than
those receiving aromatase inhibitors in the postoperative
period and exhibited lower tolerance of adverse effects
that may impair their daily activities. However, in
another study, reported in abstract form, 90 women
with pain symptoms relapsing after surgical and medical
treatments were randomized to receive either anastro-
zole and goserelin or goserelin alone for six months
[14]. After a follow-up of at least two years, patients
receiving the double drug regimen showed a signifi-
cantly lower relapse of pain than those receiving gosere-
lin alone; however, no adverse effect of aromatase
inhibitors was reported and there was no evidence of
higher discontinuation rates in patients receiving the
double-drug regimen. The reasons of these differences
in the incidence of adverse effects and discontinuation
rate remain unclear. It is possible that the monthly con-
sultations performed in the current study increased the
reporting of adverse effects.
This study confirms the previous finding that com-
bined administration of aromatase inhibitors and gona-
dotropin-releasing hormone analogues for 6 months is
associated with a reduction in bone mineral density
[13]. However, at the completion of treatment, no signif-
icant change in mineral bone density was observed in
w o m e ni n c l u d e di ng r o u pNc o n f i r m i n go u ro w np r e -
vious observations [9,11] and by other authors [8]. This
finding might be explained by evidence that norethister-
one acetate may have a positive effect on bone metabo-
lism [27]. In fact, a small fraction of norethisterone
acetate (between 0.20 and 0.33%) is converted to ethinyl
estradiol [28].
Although the current study was ended preterm, our
results confirm that aromatase inhibitors combined with
ovarian suppressive agents significantly reduce the sever-
ity of endometriosis-related pain symptoms [1]. No sig-
nificant difference was observed in the reduction in pain
symptoms between patients receiving triptorelin and
those receiving norethisterone acetate. However, because
of the small number of patients included in the study,
no definitive conclusion can be drawn regarding the
effectiveness of the two treatments in reducing the
severity of pain symptoms in women with rectovaginal
endometriosis.
Previous studies examined the changes in the volume
of rectovaginal endometriotic nodules during hormonal
therapy demonstrating that the administration of pro-
gestin [23], oral contraceptive pill [23], vaginal danazol
[29], gonadotropin-releasing hormone analogue [30] and
the levonorgestrel intrauterine device [31] for 6 to 12
months significantly reduces the size of rectovaginal
endometriotic nodules. The current study combining
letrozole with either progestin or gonadotropin-releasing
hormone analogue confirmed that hormonal therapy
significantly decreases the volume of rectovaginal endo-
metriotic nodules. Interestingly, it was observed that the
patients receiving triptorelin had a significantly higher
percentage reduction in the volume of the nodules than
those receiving norethisterone acetate.
Conclusions
In conclusion, the current study confirms the efficacy of
aromatase inhibitors in treating endometriosis-related
pain symptoms. Because of the small number of patients
included in the study, a definitive conclusion cannot be
drawn on the superior efficacy of one treatment over
the other in relieving pain symptoms caused by rectova-
ginal endometriosis. This study shows, for the first time,
that co-treatment with progestin is more accepted by
the patients. In fact, combining the aromatase inhibitor
with gonadotropin-releasing hormone analogues may be
associated with a higher incidence of adverse effects
and, consequently, a higher discontinuation rate than
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on these finding, progestins should be the first line
choice to down-regulate the ovaries in premenopausal
women receiving aromatase inhibitors for the treatment
of endometriosis. Future studies might investigate
whether combined oral contraceptives have efficacy and
tolerability similar to progestins when used to suppress
ovarian activity during treatment with aromatase
inhibitors.
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